


1. 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide
1. 170569-88-7
2. Trocoxil
3. Pha-739521
4. Pha 739,521
5. Yft7x7sr77
6. Chembl28527
7. 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzene-1-sulfonamide
8. Chebi:76207
9. Mavacoxib (usan)
10. Mavacoxib [usan]
11. 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide
12. 4-[5-(4-fluoro-phenyl)-3-trifluoromethyl-pyrazol-1-yl]-benzenesulfonamide
13. 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide
14. Benzenesulfonamide, 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)-
15. Mavacoxib [usan:inn]
16. Unii-yft7x7sr77
17. Mavacoxibum
18. 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
19. Mavacoxib [inn]
20. Mavacoxib [mi]
21. Schembl212699
22. Dtxsid90168880
23. Bcp15454
24. Zinc3814698
25. Bdbm50057564
26. Mfcd28138640
27. S6685
28. Akos030241943
29. At19475
30. Mavacoxib [ema Epar Veterinary]
31. Ncgc00510931-01
32. As-78391
33. Hy-119447
34. Cs-0068402
35. D04863
36. E-6113
37. Q6794110
38. 4-[5-(4-fluorophenyl)-3-trifluoromethyl-1h-pyrazol-1-yl]benzenesulfonamide
39. 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]-benzenesulfonamide
40. Pha-739521; Pha739521; Pha 739521; Pha 739,521; Pha739,521; Pha-739,521
| Molecular Weight | 385.3 g/mol | 
|---|---|
| Molecular Formula | C16H11F4N3O2S | 
| XLogP3 | 3.1 | 
| Hydrogen Bond Donor Count | 1 | 
| Hydrogen Bond Acceptor Count | 8 | 
| Rotatable Bond Count | 3 | 
| Exact Mass | 385.05081042 g/mol | 
| Monoisotopic Mass | 385.05081042 g/mol | 
| Topological Polar Surface Area | 86.4 Ų | 
| Heavy Atom Count | 26 | 
| Formal Charge | 0 | 
| Complexity | 579 | 
| Isotope Atom Count | 0 | 
| Defined Atom Stereocenter Count | 0 | 
| Undefined Atom Stereocenter Count | 0 | 
| Defined Bond Stereocenter Count | 0 | 
| Undefined Bond Stereocenter Count | 0 | 
| Covalently Bonded Unit Count | 1 | 
For the treatment of pain and inflammation associated with degenerative joint disease in dogs in cases where continuous treatment exceeding one month is indicated.
QM01AH92